Atlantic Edge Private Wealth Management LLC Invests $2.52 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Atlantic Edge Private Wealth Management LLC bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 4,755 shares of the medical research company’s stock, valued at approximately $2,524,000. Thermo Fisher Scientific accounts for about 1.0% of Atlantic Edge Private Wealth Management LLC’s investment portfolio, making the stock its 23rd biggest position.

A number of other hedge funds have also added to or reduced their stakes in the company. Trillium Asset Management LLC increased its stake in Thermo Fisher Scientific by 1.2% in the fourth quarter. Trillium Asset Management LLC now owns 92,950 shares of the medical research company’s stock valued at $49,338,000 after acquiring an additional 1,135 shares during the last quarter. Dundas Partners LLP boosted its position in Thermo Fisher Scientific by 1.4% in the fourth quarter. Dundas Partners LLP now owns 62,651 shares of the medical research company’s stock valued at $33,255,000 after buying an additional 886 shares in the last quarter. Kingsview Wealth Management LLC boosted its position in Thermo Fisher Scientific by 10.3% in the fourth quarter. Kingsview Wealth Management LLC now owns 17,004 shares of the medical research company’s stock valued at $9,025,000 after buying an additional 1,591 shares in the last quarter. Fiera Capital Corp boosted its position in Thermo Fisher Scientific by 11.4% in the fourth quarter. Fiera Capital Corp now owns 104,836 shares of the medical research company’s stock valued at $55,646,000 after buying an additional 10,690 shares in the last quarter. Finally, Long Road Investment Counsel LLC boosted its position in Thermo Fisher Scientific by 11.0% in the fourth quarter. Long Road Investment Counsel LLC now owns 8,371 shares of the medical research company’s stock valued at $4,512,000 after buying an additional 830 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $70,873,516.56. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, SVP Michael A. Boxer sold 2,000 shares of the business’s stock in a transaction dated Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the transaction, the senior vice president now directly owns 13,083 shares in the company, valued at $7,430,359.02. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Tuesday, April 30th. The shares were sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $70,873,516.56. The disclosure for this sale can be found here. Insiders sold a total of 32,000 shares of company stock valued at $18,486,980 over the last three months. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.3 %

TMO traded down $1.85 during midday trading on Friday, hitting $595.30. The company had a trading volume of 1,398,449 shares, compared to its average volume of 1,463,725. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $227.24 billion, a price-to-earnings ratio of 38.18, a PEG ratio of 2.47 and a beta of 0.80. The stock’s 50 day moving average price is $576.74 and its 200 day moving average price is $542.01.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.26%. Thermo Fisher Scientific’s payout ratio is presently 10.01%.

Analyst Upgrades and Downgrades

TMO has been the topic of a number of recent research reports. The Goldman Sachs Group lifted their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a report on Wednesday, April 10th. HSBC lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the stock a “buy” rating in a report on Tuesday, April 30th. JPMorgan Chase & Co. lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a report on Thursday, April 25th. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Finally, Deutsche Bank Aktiengesellschaft lifted their price target on shares of Thermo Fisher Scientific from $600.00 to $610.00 and gave the stock a “buy” rating in a report on Thursday, April 25th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $607.35.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.